BRPI0407902A - modulador de ressonáncia para diagnóstico e terapia - Google Patents

modulador de ressonáncia para diagnóstico e terapia

Info

Publication number
BRPI0407902A
BRPI0407902A BRPI0407902-7A BRPI0407902A BRPI0407902A BR PI0407902 A BRPI0407902 A BR PI0407902A BR PI0407902 A BRPI0407902 A BR PI0407902A BR PI0407902 A BRPI0407902 A BR PI0407902A
Authority
BR
Brazil
Prior art keywords
resonance
modulator
resonance modulator
properties
immune
Prior art date
Application number
BRPI0407902-7A
Other languages
English (en)
Inventor
Lee Roy Morgan
Original Assignee
Dekk Tec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dekk Tec Inc filed Critical Dekk Tec Inc
Publication of BRPI0407902A publication Critical patent/BRPI0407902A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/326—Applying electric currents by contact electrodes alternating or intermittent currents for promoting growth of cells, e.g. bone cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MODULADOR DE RESSONáNCIA PARA DIAGNóSTICO E TERAPIA". A presente invenção refere-se a um método e um dispositivo para monitorar e/ou alterar uma função imune. O método usa um composto modulador de ressonância como um agente de ligação que é capaz de interagir com o sistema imune para monitorar ou estimular a função imune. O modulador de ressonância tem propriedades eletromagnéticas inerentes que atraem células imunes para uma área alvo à qual o agente modulador de ressonância foi aplicado. As propriedades eletromagnéticas (tais como uma amplitude de voltagem) da região alvo são alteradas na presença do modulador de ressonância , e servem como um indicador da função imune. Um estímulo externo (tal como um campo eletromagnético aplicado) também pode ser aplicado ao modulador de ressonância para reforçar suas propriedades imunoestimulantes e atrativas. Exemplos particulares do modulador de ressonância são aril hidrazonas que possuem as propriedades elétricas/magnéticas desejadas que permitem que funcione como um sensor/modulador. O modulador de ressonância pode ser, por exemplo, 4,4<39> dihidroxibenzofenona-2,4-dinitro-fenilhidrazona (A-007) ou 2,6-Dibenzilidenociclohexanona-2, 4-dinitrofenilhidrazona (BDP-DNP). Estas substâncias possuem movimentos dipolares intramoleculares ressonantes que são capazes de interação eletrostática com ambientes biológicos. As aril nitrohidrazonas descritas têm a capacidade de interagir com populações de células com características comportamentais emergentes associadas com alterações e lesões químicas, biológicas e por radiação. A descrição também proporciona numerosos outros exemplos de agentes moduladores de ressonância, e proporciona atributos destes agentes e testes para identificar agentes moduladores de ressonância adicionais.
BRPI0407902-7A 2003-02-28 2004-02-27 modulador de ressonáncia para diagnóstico e terapia BRPI0407902A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45087703P 2003-02-28 2003-02-28
PCT/US2004/005845 WO2004078174A1 (en) 2003-02-28 2004-02-27 Resonance modulator for diagnosis and therapy

Publications (1)

Publication Number Publication Date
BRPI0407902A true BRPI0407902A (pt) 2006-02-14

Family

ID=32962541

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407902-7A BRPI0407902A (pt) 2003-02-28 2004-02-27 modulador de ressonáncia para diagnóstico e terapia

Country Status (8)

Country Link
US (1) US20070049514A1 (pt)
EP (1) EP1603563A4 (pt)
JP (1) JP2006521381A (pt)
AU (1) AU2004218474A1 (pt)
BR (1) BRPI0407902A (pt)
CA (1) CA2517355A1 (pt)
MX (1) MXPA05009182A (pt)
WO (1) WO2004078174A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007013762A (es) * 2005-05-04 2008-03-14 Dekk Tec Inc Compuestos aromaticos conjugados para diagnostico y terapia.
RS53599B1 (sr) 2005-05-10 2015-02-27 Intermune, Inc. Piridon derivati za modulaciju stresom aktiviranog sistema proteinskih kinaza
TW200800145A (en) 2005-08-26 2008-01-01 Dekk Tec Inc Hydrazone agents to treat cutaneous lesions
EP2142498A2 (en) * 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
US20150018294A1 (en) * 2012-02-07 2015-01-15 Arrigo DE BENEDETTI Modulators of tousled kinase in cellular processes
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
EP3439736A1 (en) 2016-04-04 2019-02-13 General Electric Company Techniques for neuromodulation
CN111632275B (zh) * 2019-03-01 2023-04-28 天津工业大学 可塑性诱导不同时间段低频磁刺激调控突触可塑性的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732904A (en) * 1984-12-24 1988-03-22 Morgan Lee R Antiestrogenic hydrazones
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
DE3903990A1 (de) * 1989-02-10 1990-08-30 Basf Ag Phenylhydrazone, ihre herstellung und daraus hergestellte arzneimittel und kosmetika
US5270172A (en) * 1991-04-26 1993-12-14 Dekk-Tek, Inc. Method to predict tumor response to therapy
US6038478A (en) * 1997-10-16 2000-03-14 Huntingdon Medical Research Institutes Lymphocyte attraction by electrical stimulation
JP2002047199A (ja) * 2000-07-27 2002-02-12 Michishi Tani 生薬の効力増強方法

Also Published As

Publication number Publication date
WO2004078174A1 (en) 2004-09-16
EP1603563A4 (en) 2007-08-22
EP1603563A1 (en) 2005-12-14
CA2517355A1 (en) 2004-09-16
AU2004218474A1 (en) 2004-09-16
US20070049514A1 (en) 2007-03-01
MXPA05009182A (es) 2006-05-19
JP2006521381A (ja) 2006-09-21

Similar Documents

Publication Publication Date Title
Zhao et al. Permanent fluidic magnets for liquid bioelectronics
Huang Action of antimicrobial peptides: two-state model
Dolev et al. Design of nanorobots for exposing cancer cells
Schoenbach et al. Bioelectric effects of intense nanosecond pulses
Schenck Safety of strong, static magnetic fields
BRPI0407902A (pt) modulador de ressonáncia para diagnóstico e terapia
Isogai et al. Ceragenin CSA‐13 exhibits antimicrobial activity against cariogenic and periodontopathic bacteria
Carvalho et al. Magnetic dehydrodipeptide-based self-assembled hydrogels for theragnostic applications
WO2007027843A3 (en) Nmr device for detection of analytes involving magnetic particles
Graham et al. New devices to deliver somatosensory stimuli during functional MRI
Adair Static and low-frequency magnetic field effects: health risks and therapies
Landers et al. Simultaneous study of brownian and neel relaxation phenomena in ferrofluids by mossbauer spectroscopy
Dogan et al. Remotely guided immunobots engaged in anti‐tumorigenic phenotypes for targeted cancer immunotherapy
Sadri et al. Static magnetic field effect on cell alignment, growth, and differentiation in human cord-derived mesenchymal stem cells
Acri et al. dB/dt evaluation in MRI sites: is ICNIRP threshold limit (for workers) exceeded?
Hornemann et al. Biopolymer and water dynamics in microbial biofilm extracellular polymeric substance
Su et al. Structures of β-hairpin antimicrobial protegrin peptides in lipopolysaccharide membranes: mechanism of gram selectivity obtained from solid-state nuclear magnetic resonance
Fyhrquist et al. New findings in allergic contact dermatitis
Ijaz et al. Attenuative effects of tamarixetin against polystyrene microplastics‐induced hepatotoxicity in rats by regulation of Nrf‐2/Keap‐1 pathway
Takagi et al. Antimicrobial activity of a bovine myeloid antimicrobial peptide (BMAP‐28) against methicillin‐susceptible and methicillin‐resistant Staphylococcus aureus
Bratborska et al. Skin microbiome and radiation-induced skin injury: unraveling the relationship, mechanisms, and therapeutic implications
Busch et al. Advanced skin antisepsis: application of UVA-Cleavable hydroxyethyl starch nanocapsules for Improved Eradication of Hair follicle-Associated microorganisms
Stuchly Electromagnetic fields and health
Lucia et al. Investigating the impact of electromagnetic fields on human cells: A thermodynamic perspective
Kranjc et al. Determination of the impact of high-intensity pulsed electromagnetic fields on the release of damage-associated molecular pattern molecules

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.